Related Experiment Video
Updated: Jun 10, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?
Josep Gamez1, Carles Lorenzo-Bosquet, Gemma Cuberas-Borrós
1Neurology Department, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119, Barcelona, Spain.
Objective:
To evaluate the usefulness of SPECT in assessing damage to the pre-synaptic dopaminergic system in Huntington's disease (HD) using [(123)I]-FP-CIT (DaTSCAN), a selective radioligand with regulatory approval as the diagnostic test for investigating functional dopaminergic neuron loss in the striatum in Parkinson's disease.
Methods:
We studied twelve symptomatic HD patients using DaTSCAN/SPECT imaging. [(123)I]-FP-CIT caudate and putamen uptake levels were qualitatively and semi-quantitatively analyzed to assess pre-synaptic damage in the striatal dopamine system. Possible correlations were analyzed between HD severity on the Unified Huntington's Disease Rating Scale (UHDRS), duration of clinical symptoms, and [(123)I]-FP-CIT/SPECT striatal uptake.
Results:
DaTSCAN/SPECT qualitative analysis showed reduced striatal uptake in eight patients. Semi-quantitative analysis revealed a significant reduction in four. Of these four, uptake reduction was at putamen level in all, and also at caudate level in one. Although we observed no linear correlation between HD severity and reduced striatal [(123)I]-FP-CIT uptake, the patients with the worst UHDRS scores had more severe reductions in radioligand uptake.
Conclusion:
This is the first study to use in vivo [(123)I]-FP-CIT/SPECT imaging to confirm prior descriptions using PET of a pre-synaptic dopaminergic system defect in HD.
More Related Videos
Related Concept Videos
Huntington Disease l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Drugs Affecting Neurotransmitter Release or Uptake

